JP6946290B2 - Ｍｎｋ阻害剤としてのピロロピリミジン化合物 - Google Patents
Ｍｎｋ阻害剤としてのピロロピリミジン化合物 Download PDFInfo
- Publication number
- JP6946290B2 JP6946290B2 JP2018525743A JP2018525743A JP6946290B2 JP 6946290 B2 JP6946290 B2 JP 6946290B2 JP 2018525743 A JP2018525743 A JP 2018525743A JP 2018525743 A JP2018525743 A JP 2018525743A JP 6946290 B2 JP6946290 B2 JP 6946290B2
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- tumors
- substituted
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 ***(*)=*(*)*(*)=C(C(O*)=I)Nc1c2[n](*)c(*)c(*)c2ncn1 Chemical compound ***(*)=*(*)*(*)=C(C(O*)=I)Nc1c2[n](*)c(*)c(*)c2ncn1 0.000 description 2
- XKHKDMBSKXQTDF-UHFFFAOYSA-N CC(C)Oc(cc(cc1)F)c1Nc1ncnc2c1[n](CCOC)cc2 Chemical compound CC(C)Oc(cc(cc1)F)c1Nc1ncnc2c1[n](CCOC)cc2 XKHKDMBSKXQTDF-UHFFFAOYSA-N 0.000 description 1
- ZEYCPHWYYVXEMM-UHFFFAOYSA-N CC(C)Oc(cc(cc1)OC)c1Nc1c2[n](C)ccc2ncn1 Chemical compound CC(C)Oc(cc(cc1)OC)c1Nc1c2[n](C)ccc2ncn1 ZEYCPHWYYVXEMM-UHFFFAOYSA-N 0.000 description 1
- GAHYGKWQUAYORK-UHFFFAOYSA-N CSc1c2[nH]ccc2ncn1 Chemical compound CSc1c2[nH]ccc2ncn1 GAHYGKWQUAYORK-UHFFFAOYSA-N 0.000 description 1
- BQRBGBJWLOFQFC-HOTGVXAUSA-N C[n]1c2c(Nc(ccc(F)c3)c3O[C@@H](CCCC3)[C@H]3O)ncnc2cc1 Chemical compound C[n]1c2c(Nc(ccc(F)c3)c3O[C@@H](CCCC3)[C@H]3O)ncnc2cc1 BQRBGBJWLOFQFC-HOTGVXAUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1520499.3 | 2015-11-20 | ||
| GBGB1520499.3A GB201520499D0 (en) | 2015-11-20 | 2015-11-20 | Compounds |
| PCT/GB2016/053579 WO2017085483A1 (en) | 2015-11-20 | 2016-11-16 | Pyrropyrimidine compounds as mnks inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534316A JP2018534316A (ja) | 2018-11-22 |
| JP2018534316A5 JP2018534316A5 (enExample) | 2019-12-26 |
| JP6946290B2 true JP6946290B2 (ja) | 2021-10-06 |
Family
ID=55133105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525743A Expired - Fee Related JP6946290B2 (ja) | 2015-11-20 | 2016-11-16 | Ｍｎｋ阻害剤としてのピロロピリミジン化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10604524B2 (enExample) |
| EP (2) | EP3377494B1 (enExample) |
| JP (1) | JP6946290B2 (enExample) |
| CN (1) | CN108368114B (enExample) |
| AU (1) | AU2016355103B2 (enExample) |
| CA (1) | CA3003554C (enExample) |
| ES (2) | ES2972862T3 (enExample) |
| GB (1) | GB201520499D0 (enExample) |
| WO (1) | WO2017085483A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| ES2969988T3 (es) | 2017-02-14 | 2024-05-23 | Effector Therapeutics Inc | Inhibidores de Mnk sustituidos con piperidina y métodos relacionados con los mismos |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| WO2020086713A1 (en) | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| CN110903286B (zh) * | 2019-12-16 | 2021-09-24 | 沈阳药科大学 | 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| SK72996A3 (en) * | 1995-06-07 | 1997-04-09 | Pfizer | Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base |
| KR20000057228A (ko) * | 1996-11-27 | 2000-09-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 축합된 비사이클릭 피리미딘 유도체 |
| JP2004509059A (ja) | 1999-06-03 | 2004-03-25 | アボット・ラボラトリーズ | 細胞接着抑制性抗炎症化合物 |
| US20050165029A1 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| EP1773826A4 (en) | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| TW200730527A (en) * | 2005-12-02 | 2007-08-16 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| US8633201B2 (en) * | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| EP2219649A2 (en) * | 2007-11-22 | 2010-08-25 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP5626748B2 (ja) * | 2008-07-02 | 2014-11-19 | キッコーマン株式会社 | ペプチド含有調味料 |
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| EP2539343B1 (en) | 2010-02-26 | 2015-12-30 | Evotec International GmbH | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| ES2653419T3 (es) | 2013-02-01 | 2018-02-07 | Bayer Pharma Aktiengesellschaft | Pirazolopirimidinilamino-indazoles sustituidos |
| US9675612B2 (en) | 2013-03-06 | 2017-06-13 | Bayer Pharma Aktiengesellschaft | Substituted thiazolopyrimidines |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
-
2015
- 2015-11-20 GB GBGB1520499.3A patent/GB201520499D0/en not_active Ceased
-
2016
- 2016-11-16 ES ES20204385T patent/ES2972862T3/es active Active
- 2016-11-16 EP EP16801015.5A patent/EP3377494B1/en active Active
- 2016-11-16 CA CA3003554A patent/CA3003554C/en active Active
- 2016-11-16 AU AU2016355103A patent/AU2016355103B2/en not_active Ceased
- 2016-11-16 CN CN201680067666.6A patent/CN108368114B/zh not_active Expired - Fee Related
- 2016-11-16 JP JP2018525743A patent/JP6946290B2/ja not_active Expired - Fee Related
- 2016-11-16 WO PCT/GB2016/053579 patent/WO2017085483A1/en not_active Ceased
- 2016-11-16 ES ES16801015T patent/ES2872775T3/es active Active
- 2016-11-16 EP EP20204385.7A patent/EP3792264B1/en active Active
- 2016-11-16 US US15/776,574 patent/US10604524B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018534316A (ja) | 2018-11-22 |
| EP3792264A1 (en) | 2021-03-17 |
| EP3792264B1 (en) | 2024-01-03 |
| CA3003554A1 (en) | 2017-05-26 |
| CN108368114B (zh) | 2023-10-24 |
| EP3377494A1 (en) | 2018-09-26 |
| CA3003554C (en) | 2023-08-29 |
| AU2016355103B2 (en) | 2021-07-08 |
| AU2016355103A1 (en) | 2018-05-31 |
| HK1253576A1 (en) | 2019-06-21 |
| WO2017085483A1 (en) | 2017-05-26 |
| ES2972862T3 (es) | 2024-06-17 |
| EP3377494B1 (en) | 2021-03-03 |
| US10604524B2 (en) | 2020-03-31 |
| GB201520499D0 (en) | 2016-01-06 |
| CN108368114A (zh) | 2018-08-03 |
| US20180346469A1 (en) | 2018-12-06 |
| ES2872775T3 (es) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2403853B1 (en) | Pyrrolopyrimidines used as kinase inhibitors | |
| JP7181647B2 (ja) | Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 | |
| JP6946290B2 (ja) | Ｍｎｋ阻害剤としてのピロロピリミジン化合物 | |
| JP2013529196A (ja) | キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン | |
| JP2008525463A (ja) | ＪＡＮＵＳキナーゼ阻害剤としてのピロロ［２，３−ｂ］ピリジン−４−イル−アミンおよびピロロ［２，３−ｂ］ピリミジン−４−イル−アミン | |
| CN110407839B (zh) | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 | |
| HK40037886A (en) | Pyrropyrimidine compounds as mnks inhibitors | |
| HK40037886B (en) | Pyrropyrimidine compounds as mnks inhibitors | |
| EP4384518B1 (en) | Tyrosine kinase inhibitors | |
| HK1253576B (en) | Pyrropyrimidine compounds as mnks inhibitors | |
| HK40065647A (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| HK40065647B (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| CN108117551A (zh) | 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途 | |
| Webb-Smith | 2) Patent Application Publication o Pub. No.: US 2020/0247822 A1 | |
| HK1253575B (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210708 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210915 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6946290 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |